Core Viewpoint - Scholar Rock is conducting a BLA resubmission call to discuss its expectations, plans, and prospects regarding its product pipeline and future developments [1][2][3] Group 1: Company Overview - Laura Ekas serves as the Vice President of Investor Relations at Scholar Rock, leading the call alongside key executives including the CEO, President of R&D, COO, and CFO [2] - The management team will provide remarks followed by a Q&A session to address investor inquiries [2] Group 2: Forward-Looking Statements - The call includes forward-looking statements that reflect the company's views as of the date of the call, emphasizing that these statements should not be relied upon as definitive future outcomes [3]

Scholar Rock (NasdaqGS:SRRK) Update / briefing March 31, 2026 08:00 AM ET Company ParticipantsAkshay Vaishnaw - President of R&DAmy Li - SVP of Biotechnology and Large Cap Pharma Equity ResearchConor MacKay - VP of Equity ResearchDavid Hallal - Chairman and CEOJarwei Fang - VP of Large Cap Biotechnology and Pharma Equity ResearchKeith Woods - COOKripa Devarakonda - VP of Biotechnology Equity ResearchKyle Yang - Associate Director of Pharma and BiotechLaura Ekas - VP of Investor RelationsTazeen Ahmad - Manag ...

Summary of Scholar Rock Conference Call Company Overview - **Company**: Scholar Rock (NasdaqGS:SRRK) - **Focus**: Development of Apitegromab, a muscle-targeted therapy for Spinal Muscular Atrophy (SMA) Key Points Industry Context - The conference highlighted the challenges faced by biotech companies, particularly in drug development and regulatory compliance, with a specific focus on the manufacturing issues related to the Catalent Novo facility [6][7][8]. Apitegromab Development - **Phase 3 Trial**: Scholar Rock announced positive results from the phase 3 SAPPHIRE trial involving 188 patients, achieving statistically significant improvements in motor function for SMA patients [6]. - **Regulatory Timeline**: The company filed for approval in January 2025, received priority review, and had an action date set for September 22, 2025. However, a complete response letter was issued due to compliance issues at the manufacturing facility [7][14]. Manufacturing and Compliance Issues - The compliance issue was specifically related to the third-party fill-finish manufacturing facility in Bloomington, Indiana, which is now owned by Novo Nordisk [7][10]. - Following a Type A meeting with the FDA, there has been a positive progression in communication and remediation efforts at the facility, with expectations for a formal re-inspection soon [11][12][13]. Resubmission and Launch Plans - Scholar Rock reaffirmed its guidance for a BLA resubmission and U.S. launch in 2026, contingent on the successful re-inspection of the manufacturing facility [14][25]. - The company is also working on a second fill-finish facility to ensure redundancy in its supply chain, which is expected to support the 2026 launch [19][20]. Supply and Inventory Management - Scholar Rock has tens of thousands of vials of Apitegromab ready for the SMA community, which were manufactured before the compliance issues arose [22][23]. - The company is confident that the existing inventory will meet initial demand upon approval, with additional supply expected from the second facility [25]. Commercial Readiness - The commercial team has been actively preparing for the launch, including disease awareness campaigns and building relationships with treatment centers and payers [32][33]. - A patient assistance program, Scholar Rock Supports, has been established to help patients navigate the reimbursement process [35]. Global Market Opportunity - The company anticipates a significant global market for Apitegromab, with expectations of a balanced distribution of sales between the U.S., Europe, and other regions [43][46]. - There are approximately 35,000 patients globally who have received SMN-targeted therapies, indicating a robust market opportunity for Apitegromab [46]. Future Development Plans - Scholar Rock is exploring additional formulations and indications for Apitegromab, including subcutaneous delivery options and new therapies like SRK-439, a myostatin inhibitor [52][53]. Financial Position - The company announced a new loan of up to $550 million to support its operations and pipeline without diluting equity, maintaining a strong balance sheet with $368 million at year-end [57][58]. Conclusion - Scholar Rock is navigating significant regulatory and manufacturing challenges but remains optimistic about the approval and launch of Apitegromab in 2026. The company is also strategically positioning itself for future growth in the neuromuscular disease space.

Core Insights - Redmile Group increased its stake in Scholar Rock Holding Corporation by purchasing 1,316,390 shares, valued at approximately $49.37 million based on quarterly average pricing [1][2] - The quarter-end value of Redmile's position in Scholar Rock increased by $84.58 million, reflecting both the acquisition of additional shares and market price movements [2] Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies that modulate protein growth factor signaling, addressing unmet medical needs in neuromuscular, oncological, and fibrotic indications [6] - The company has a proprietary platform and is positioned to capitalize on innovative science in high-impact therapeutic areas through strategic collaborations and a focused pipeline [6] Financial Metrics - As of February 17, 2026, Scholar Rock's stock price was $46.45, with a market capitalization of $4.78 billion [4] - The company reported a net income of -$353.43 million (TTM) and a one-year price change of 25.71% [4] Investment Implications - The purchase by Redmile Group indicates a strong commitment to Scholar Rock, which now represents approximately 17% of the fund's assets under management [7][10] - Scholar Rock is expected to submit a Biologics License Application for apitegromab in spinal muscular atrophy, with a potential U.S. launch anticipated following approval this year [9] - The company had approximately $365 million in cash as of December 31, providing a runway into 2027 and reducing near-term dilution risk for investors [9] Market Performance - Scholar Rock's shares have increased by about 26% over the past year, outperforming the broader market and indicating that investors are recognizing the value of regulatory progress and pipeline depth [11] - The company is also developing additional programs, including FSHD and the SRK-439 myostatin inhibitor, which expand its potential market opportunities [11]

Scholar Rock (NasdaqGS:SRRK) FY Conference Summary Company Overview - **Company**: Scholar Rock - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **Key Speaker**: David Hallal, Chairman and CEO Core Industry and Company Insights - Scholar Rock is positioned as a leader in myostatin biology, focusing on treatments for rare neuromuscular disorders, particularly Spinal Muscular Atrophy (SMA) [2][3] - The company has developed Apitegromab, the first myostatin inhibitor to successfully complete a pivotal phase III study, demonstrating clinically meaningful benefits for SMA patients [3][10] - Apitegromab is expected to receive U.S. and European approvals in 2026, with Germany being the initial launch country in Europe [3][5] Key Developments and Milestones - Scholar Rock plans to initiate dosing for a new indication of Apitegromab for Facioscapulohumeral Muscular Dystrophy (FSHD) later in 2026 [4][19] - The company has a strong cash position of approximately $365 million, providing a runway into 2027 to support commercial and R&D initiatives [25] - The phase III trial data showed that about one-third of patients receiving Apitegromab alongside SMN-targeted therapies had significant improvements in motor function, compared to only 12.5% in the placebo group [12] Market Opportunity - The global market for SMN-targeted therapies is projected to reach $5 billion in 2025, with Apitegromab representing a $2 billion-plus opportunity specifically for SMA [18][27] - The company aims to build a 50-country operating platform to serve SMA patients globally, with a focus on the U.S., Europe, and significant markets in Asia-Pacific and Latin America [6][7] Regulatory and Commercial Strategy - Scholar Rock is preparing for a BLA resubmission and U.S. launch following a complete response letter from the FDA, which was related to site inspection issues rather than clinical efficacy [13][15] - The company is actively engaging with national and regional payers to educate them on the unmet needs in SMA and the potential benefits of Apitegromab [16][17] - The U.S. commercial team is focused on disease education and building relationships with the SMA community to ensure successful market entry [16] Future Directions - Scholar Rock is committed to expanding the reach of Apitegromab to ensure no SMA patient is left behind, including those under two years of age [19][26] - The company is also exploring additional neuromuscular diseases for which Apitegromab may provide therapeutic benefits [22][23] - Ongoing development of SRK-439, a more potent myostatin inhibitor, is also a priority, with plans to share data from healthy volunteer studies in late 2026 [24] Financial Outlook - The company has maintained financial discipline while investing in high-value programs, with a focus on preparing for the commercial launch of Apitegromab [25][41] - There is an expectation of strong demand for Apitegromab upon approval, with plans for non-dilutive financing options to support operational needs [41] Conclusion - Scholar Rock is poised for a transformative year in 2026, with significant advancements in the treatment of SMA and a robust pipeline aimed at addressing various neuromuscular disorders [26]

Core Viewpoint - The article emphasizes a focus on non-consensus long-short investment ideas within the biotechnology sector, particularly targeting small to mid-cap companies in the US and EU markets, with an interest in clinical catalysts and new drug launches [1]. Group 1: Investment Focus - The investment strategy centers on small to mid-cap biotechnology companies that are publicly traded [1]. - The analysis aims to identify clinical catalysts that could influence stock performance and earnings related to new drug launches [1]. Group 2: Analyst's Position - The analyst holds a beneficial long position in the shares of SRRK, indicating a personal investment interest in this specific stock [2]. - The article is authored by the analyst without external compensation, reflecting personal opinions rather than institutional views [2]. Group 3: Content Disclaimer - The content is intended for informational and educational purposes only, and should not be interpreted as financial or investment advice [3]. - The article acknowledges the possibility of errors or inaccuracies in the information provided, emphasizing the need for readers to conduct their own due diligence [3].

Core Insights - Commodore Capital has fully exited its position in Scholar Rock Holding Corporation, selling approximately 1.5 million shares in Q3, which represented a net position change of about $51 million [1][2][10] Company Overview - Scholar Rock Holding Corporation is a biotechnology company focused on developing therapeutics for serious diseases driven by protein growth factor signaling, with a pipeline that includes neuromuscular, oncology, and fibrotic indications [5][8] - As of the latest data, Scholar Rock's share price is $41.08, with a market capitalization of $4.2 billion and a net income of -$353.4 million over the trailing twelve months [4][8] Financial Performance - The company reported a significant increase in Q3 operating expenses, rising to $103.6 million from $64.8 million the previous year, leading to a quarterly net loss of $102.2 million [11] - Scholar Rock has $369.6 million in cash, providing a runway into 2027 to support its programs through key catalysts expected in 2026 [11] Regulatory and Market Position - Scholar Rock is preparing to resubmit its apitegromab biologics license application following a constructive FDA meeting on November 12, which indicated progress in remediation efforts [10] - The company is entering a critical phase with potential regulatory milestones that could significantly impact its market position and investor sentiment [9][12]

Core Viewpoint - Scholar Rock's stock price surged by 6% following a bullish initiation of coverage by Bank of America Securities, despite a slight decline in the S&P 500 index [1][2]. Group 1: Analyst Coverage - Tazeen Ahmad of Bank of America Securities initiated coverage on Scholar Rock, setting a buy rating with a price target of $53 per share, which is nearly 30% higher than the company's recent closing price [2]. - The positive market reaction was attributed to the analyst's favorable outlook on the company's potential [2]. Group 2: Pipeline Drug - Scholar Rock's investigational drug apitegromab, aimed at treating spinal muscular atrophy (SMA), is highlighted as significantly more effective than existing treatments [3]. - The company focuses on developing therapies for rare diseases that currently lack effective treatments [4]. - Apitegromab is the most advanced drug in Scholar Rock's pipeline and has been submitted for FDA approval under a biologics license application (BLA) [5]. - The FDA issued a complete response letter (CRL) last month, indicating that the application is not approved in its current form, and Scholar Rock is addressing the issues raised [5].

Group 1 - The article discusses Scholar Rock Holding Corporation (NASDAQ: SRRK) and its potential beyond its current focus on Spinal Muscular Atrophy (SMA) treatments, particularly highlighting upcoming data related to obesity treatment expected in Q2 2025 [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] - The service offers a subscription model with a promotional two-week free trial and a discounted annual plan [1] Group 2 - The article does not provide specific financial data or performance metrics related to Scholar Rock or the broader biotech industry [4]

Group 1 - The article discusses Scholar Rock Holding Corporation (NASDAQ: SRRK) and its potential beyond its current focus on Spinal Muscular Atrophy (SMA) treatments, particularly highlighting upcoming data related to obesity treatment expected in Q2 2025 [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2] - The service offers a subscription model with a promotional two-week free trial and a discounted annual plan [1] Group 2 - The article does not provide specific financial data or performance metrics related to Scholar Rock or the broader biotech industry [3][4]